# Addus HomeCare Corp: financial statements, quarterly

ADUS · Nasdaq · CIK 1468328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adus.md) · [Financials](/companies/adus/financials.md) · [Filings](/companies/adus/filings.md) · [Insiders](/companies/adus/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adus/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [271](/filings/0000950170-24-121448.md) | [276 d](/filings/0001437749-26-005352.md) | [281](/filings/0000950170-25-064522.md) | [287](/filings/0001437749-25-024871.md) | [290](/filings/0001437749-25-033041.md) | [297 d](/filings/0001437749-26-005352.md) | [338](/filings/0001437749-26-014900.md) | [349](/filings/0001437749-26-025678.md) | [362](/filings/0001437749-25-033041.md) | [373 d](/filings/0001437749-26-005352.md) | [364](/filings/0001437749-26-014900.md) | [377](/filings/0001437749-26-025678.md) |
| Cost of revenue | $m | [184](/filings/0000950170-24-121448.md) | [184 d](/filings/0001437749-26-005352.md) | [193](/filings/0000950170-25-064522.md) | [194](/filings/0001437749-25-024871.md) | [198](/filings/0001437749-25-033041.md) | [196 d](/filings/0001437749-26-005352.md) | [230](/filings/0001437749-26-014900.md) | [236](/filings/0001437749-26-025678.md) | [246](/filings/0001437749-25-033041.md) | [249 d](/filings/0001437749-26-005352.md) | [248](/filings/0001437749-26-014900.md) | [256](/filings/0001437749-26-025678.md) |
| Gross profit | $m | [86.7](/filings/0000950170-24-121448.md) | [92.4 d](/filings/0001437749-26-005352.md) | [88.2](/filings/0000950170-25-064522.md) | [93.2](/filings/0001437749-25-024871.md) | [92.2](/filings/0001437749-25-033041.md) | [101 d](/filings/0001437749-26-005352.md) | [108](/filings/0001437749-26-014900.md) | [114](/filings/0001437749-26-025678.md) | [117](/filings/0001437749-25-033041.md) | [124 d](/filings/0001437749-26-005352.md) | [116](/filings/0001437749-26-014900.md) | [122](/filings/0001437749-26-025678.md) |
| Operating income | $m | [22.8](/filings/0000950170-24-121448.md) | [28.0 d](/filings/0001437749-26-005352.md) | [23.6](/filings/0000950170-25-064522.md) | [26.2](/filings/0001437749-25-024871.md) | [26.0](/filings/0001437749-25-033041.md) | [26.9 d](/filings/0001437749-26-005352.md) | [30.5](/filings/0001437749-26-014900.md) | [32.9](/filings/0001437749-26-025678.md) | [32.9](/filings/0001437749-25-033041.md) | [42.3 d](/filings/0001437749-26-005352.md) | [34.1](/filings/0001437749-26-014900.md) | [38.9](/filings/0001437749-26-025678.md) |
| Interest expense | $m | [3.2](/filings/0000950170-24-121448.md) | [3.1 d](/filings/0000950170-24-021284.md) | [2.8](/filings/0000950170-24-054603.md) | [2.1](/filings/0000950170-24-091763.md) | [0.6](/filings/0000950170-24-121448.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [4.8](/filings/0000950170-24-121448.md) | [5.8 d](/filings/0001437749-26-005352.md) | [5.5](/filings/0000950170-25-064522.md) | [6.5](/filings/0001437749-25-024871.md) | [7.1](/filings/0001437749-25-033041.md) | [6.7 d](/filings/0001437749-26-005352.md) | [5.8](/filings/0001437749-26-014900.md) | [7.9](/filings/0001437749-26-025678.md) | [7.5](/filings/0001437749-25-033041.md) | [10.4 d](/filings/0001437749-26-005352.md) | [7.4](/filings/0001437749-26-014900.md) | [10.2](/filings/0001437749-26-025678.md) |
| Net income | $m | [15.4](/filings/0000950170-24-121448.md) | [19.6 d](/filings/0001437749-26-005352.md) | [15.8](/filings/0000950170-25-064522.md) | [18.1](/filings/0001437749-25-024871.md) | [20.2](/filings/0001437749-25-033041.md) | [19.5 d](/filings/0001437749-26-005352.md) | [21.2](/filings/0001437749-26-014900.md) | [22.1](/filings/0001437749-26-025678.md) | [22.8](/filings/0001437749-25-033041.md) | [29.8 d](/filings/0001437749-26-005352.md) | [25.1](/filings/0001437749-26-014900.md) | [27.6](/filings/0001437749-26-025678.md) |
| Diluted EPS | $ per share | [0.95](/filings/0000950170-24-121448.md) | not reported | [0.97](/filings/0000950170-25-064522.md) | [1.10](/filings/0001437749-25-024871.md) | [1.10](/filings/0001437749-25-033041.md) | not reported | [1.16](/filings/0001437749-26-014900.md) | [1.20](/filings/0001437749-26-025678.md) | [1.24](/filings/0001437749-25-033041.md) | not reported | [1.36](/filings/0001437749-26-014900.md) | [1.49](/filings/0001437749-26-025678.md) |
| Basic EPS | $ per share | [0.96](/filings/0000950170-24-121448.md) | not reported | [0.99](/filings/0000950170-25-064522.md) | [1.12](/filings/0001437749-25-024871.md) | [1.13](/filings/0001437749-25-033041.md) | not reported | [1.18](/filings/0001437749-26-014900.md) | [1.22](/filings/0001437749-26-025678.md) | [1.26](/filings/0001437749-25-033041.md) | not reported | [1.38](/filings/0001437749-26-014900.md) | [1.51](/filings/0001437749-26-025678.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.8](/filings/0000950170-23-056903.md) | [64.8](/filings/0000950170-25-026747.md) | [76.7](/filings/0000950170-24-054603.md) | [173](/filings/0000950170-24-091763.md) | [223](/filings/0000950170-24-121448.md) | [98.9](/filings/0000950170-25-064522.md) | [97.0](/filings/0000950170-25-064522.md) | [91.2](/filings/0001437749-25-024871.md) | [102](/filings/0001437749-25-033041.md) | [81.6](/filings/0001437749-26-025678.md) | [103](/filings/0001437749-26-014900.md) | [99.6](/filings/0001437749-26-025678.md) |
| Current assets | $m | [211](/filings/0000950170-23-056903.md) | [200](/filings/0000950170-25-026747.md) | [192](/filings/0000950170-24-054603.md) | [295](/filings/0000950170-24-091763.md) | [333](/filings/0000950170-24-121448.md) | [260](/filings/0001437749-26-005352.md) | [258](/filings/0000950170-25-064522.md) | [263](/filings/0001437749-25-024871.md) | [261](/filings/0001437749-25-033041.md) | [269](/filings/0001437749-26-025678.md) | [273](/filings/0001437749-26-014900.md) | [284](/filings/0001437749-26-025678.md) |
| Total assets | $m | [1,036](/filings/0000950170-23-056903.md) | [1,024](/filings/0000950170-25-026747.md) | [1,014](/filings/0000950170-24-054603.md) | [1,117](/filings/0000950170-24-091763.md) | [1,153](/filings/0000950170-24-121448.md) | [1,413](/filings/0001437749-26-005352.md) | [1,408](/filings/0000950170-25-064522.md) | [1,409](/filings/0001437749-25-024871.md) | [1,423](/filings/0001437749-25-033041.md) | [1,437](/filings/0001437749-26-025678.md) | [1,436](/filings/0001437749-26-014900.md) | [1,456](/filings/0001437749-26-025678.md) |
| Current liabilities | $m | [140](/filings/0000950170-23-056903.md) | [145](/filings/0000950170-25-026747.md) | [142](/filings/0000950170-24-054603.md) | [148](/filings/0000950170-24-091763.md) | [158](/filings/0000950170-24-121448.md) | [156](/filings/0001437749-26-005352.md) | [148](/filings/0000950170-25-064522.md) | [151](/filings/0001437749-25-024871.md) | [157](/filings/0001437749-25-033041.md) | [149](/filings/0001437749-26-025678.md) | [149](/filings/0001437749-26-014900.md) | [168](/filings/0001437749-26-025678.md) |
| Total liabilities | $m | [351](/filings/0000950170-23-056903.md) | [318](/filings/0000950170-25-026747.md) | [289](/filings/0000950170-24-054603.md) | [195](/filings/0000950170-24-091763.md) | [205](/filings/0000950170-24-121448.md) | [442](/filings/0001437749-26-005352.md) | [412](/filings/0000950170-25-064522.md) | [387](/filings/0001437749-25-024871.md) | [373](/filings/0001437749-25-033041.md) | [352](/filings/0001437749-26-025678.md) | [320](/filings/0001437749-26-014900.md) | [308](/filings/0001437749-26-025678.md) |
| Long-term debt | $m | [164](/filings/0000950170-23-056903.md) | [124](/filings/0000950170-25-026747.md) | [99.3](/filings/0000950170-24-054603.md) | not reported | not reported | [218](/filings/0001437749-26-005352.md) | [199](/filings/0000950170-25-064522.md) | [169](/filings/0001437749-25-024871.md) | [151](/filings/0001437749-25-033041.md) | [121](/filings/0001437749-26-025678.md) | [91.3](/filings/0001437749-26-014900.md) | [61.6](/filings/0001437749-26-025678.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [684](/filings/0000950170-24-121448.md) | [707](/filings/0001437749-26-005352.md) | [725](/filings/0001437749-25-024871.md) | [922](/filings/0001437749-25-033041.md) | [948](/filings/0001437749-25-033041.md) | [970](/filings/0001437749-26-025678.md) | [995](/filings/0001437749-26-025678.md) | [1,022](/filings/0001437749-26-025678.md) | [1,050](/filings/0001437749-25-033041.md) | [1,085](/filings/0001437749-26-025678.md) | [1,116](/filings/0001437749-26-025678.md) | [1,148](/filings/0001437749-26-025678.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [21.8 d](/filings/0000950170-24-121448.md) | [30.0 d](/filings/0001437749-26-005352.md) | [38.7](/filings/0000950170-25-064522.md) | [18.8 d](/filings/0001437749-25-024871.md) | [48.5 d](/filings/0001437749-25-033041.md) | [10.4 d](/filings/0001437749-26-005352.md) | [18.9](/filings/0001437749-26-014900.md) | [22.5 d](/filings/0001437749-26-025678.md) | [51.3 d](/filings/0001437749-25-033041.md) | [18.8 d](/filings/0001437749-26-005352.md) | [52.4](/filings/0001437749-26-014900.md) | [40.0 d](/filings/0001437749-26-025678.md) |
| Capital expenditure | $m | [2.4 d](/filings/0000950170-24-121448.md) | [5.3 d](/filings/0001437749-26-005352.md) | [1.4](/filings/0000950170-25-064522.md) | [1.1 d](/filings/0001437749-25-024871.md) | [1.9 d](/filings/0001437749-25-033041.md) | [1.7 d](/filings/0001437749-26-005352.md) | [1.9](/filings/0001437749-26-014900.md) | [1.3 d](/filings/0001437749-26-025678.md) | [1.9 d](/filings/0001437749-25-033041.md) | [2.7 d](/filings/0001437749-26-005352.md) | [1.7](/filings/0001437749-26-014900.md) | [1.3 d](/filings/0001437749-26-025678.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.2](/filings/0000950170-23-056903.md) | [16.3](/filings/0000950170-24-054603.md) | [16.3](/filings/0000950170-24-091763.md) | [16.3](/filings/0000950170-24-121448.md) | [16.4](/filings/0000950170-25-064522.md) | [16.5](/filings/0001437749-25-024871.md) | [18.3](/filings/0001437749-25-033041.md) | [18.3](/filings/0001437749-26-014900.md) | [18.3](/filings/0001437749-26-025678.md) | [18.4](/filings/0001437749-25-033041.md) | [18.5](/filings/0001437749-26-014900.md) | [18.5](/filings/0001437749-26-025678.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,674,300 at 2026-07-28, from the cover of the [10-Q filed 2026-08-04](/filings/0001437749-26-025678.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.